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Abstract
Motor neuron disease (MND) is a progressive neurodegenerative disease with no effective treatment. One of the principal 
pathological hallmarks is the deposition of TAR DNA binding protein 43 (TDP-43) in cytoplasmic inclusions. TDP-43 aggre-
gation occurs in both familial and sporadic MND; however, the mechanism of endogenous TDP-43 aggregation in disease 
is incompletely understood. This study focused on the induction of cytoplasmic accumulation of endogenous TDP-43 in the 
motor neuronal cell line NSC-34. The endoplasmic reticulum (ER) stressor tunicamycin induced casein kinase 1 (CK1)-
dependent cytoplasmic accumulation of endogenous TDP-43 in differentiated NSC-34 cells, as seen by immunocytochem-
istry. Immunoblotting showed that induction of ER stress had no effect on abundance of TDP-43 or phosphorylated TDP-43 
in the NP-40/RIPA soluble fraction. However, there were significant increases in abundance of TDP-43 and phosphorylated 
TDP-43 in the NP-40/RIPA-insoluble, urea-soluble fraction, including high molecular weight species. In all cases, these 
increases were lowered by CK1 inhibition. Thus ER stress signalling, as induced by tunicamycin, causes CK1-dependent 
phosphorylation of TDP-43 and its consequent cytosolic accumulation.
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Abbreviations
Cdk  Cyclin-dependent kinase
CK  Casein kinase
CHOP  C/EBP homologous protein
ERK  Extracellular signal regulated kinase
FUS  Fused in sarcoma
G3BP1  Ras GTPase-activating protein-binding 
protein 1
GSK-3β  Glycogen synthase kinase-3 beta
JNK  c-Jun N-terminal kinase
MND  Motor neuron disease
PDI  Protein disulphide isomerase
RRID  Research resource identifier
SG  Stress granule
(p) TDP-43  (phosphorylated) TAR DNA binding protein 
43
TIAR  T-intracellular antigen-1 cytotoxic granule-
associated RNA binding protein-like 1
Introduction
Motor neuron disease (MND, also known as amyotrophic 
lateral sclerosis) is a progressive, incurable and ultimately 
fatal neurodegenerative disease [1]. Ongoing loss of motor 
neurons in the brainstem, motor cortex and spinal cord leads 
to muscle weakness, then subsequently paralysis and death 
[2]. In a minority of cases (approximately 10%), there is a 
familial background, with mutations in the genes encoding 
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proteins such as superoxide dismutase 1 (SOD1) [3], TAR 
DNA binding protein 43 (TDP-43) [4], fused in sarcoma 
(FUS) [5, 6], and C9ORF72 [7, 8]. However, the vast major-
ity of cases are sporadic, with no discovered genetic basis 
[1].
One of the key pathological hallmarks of MND (both 
sporadic and familial) is the presence of TDP-43 inclusions 
in motor neurons [9, 10], although not in SOD1-linked MND 
[10] In familial MND with mutations in the TARDBP gene 
(encoding TDP-43), the disease-causing mutations cluster 
in the TDP-43 C-terminal region [4]. TDP-43 aggregation, 
which can be caused by mutations in a minority of cases, 
has been demonstrated to interfere with nucleocytoplas-
mic transport and compounds capable of blocking TDP-
43 aggregation in C. elegans have been discovered which 
improve viability [11–16]. It is not yet clear whether the 
TDP-43 aggregates result in toxicity via loss of function of 
the nuclear protein, or whether the aggregates confer a toxic 
gain of function [17–19].
The mechanisms underlying TDP-43 aggregation in 
sporadic MND are incompletely characterized, although 
phosphorylation of TDP-43 is likely to be important [20]. 
TDP-43 is a substrate for a number of protein kinases—
casein kinase 1 (CK1) has been identified as a direct TDP-43 
kinase, including at S409/410 [21–25], and its overexpres-
sion can induce TDP-43 phosphorylation [26]. Furthermore, 
custom synthesized CK1δ inhibitors were able to reduce 
TDP-43 phosphorylation and protect cultured cells against 
ethacrynic acid challenge, which induces neuroblastoma cell 
death by mediating the phosphorylation of TDP-43 [27]. In 
addition, there has been substantial interest in developing 
CK1 inhibitors for MND [28–30].
While the specific pathological drivers of sporadic MND 
are largely uncharacterized, TDP-43 inclusions are some-
what reminiscent of stress granules (SGs) [31]—many cel-
lular stresses have been shown to cause formation of SGs, 
which stain positive for T-intracellular antigen-1 cytotoxic 
granule-associated RNA binding protein-like 1 (TIAR) and 
Ras GTPase-activating protein-binding protein 1 (G3BP1) 
[32, 33]. SGs are seen in MND spinal cord and G3BP1-
positive inclusions are found in the brains of mice expressing 
the  G4C2 hexanucleotide expansion found in the C9ORF72 
non-coding region, which also exhibit TDP-43 deposition 
[34, 35]. However, it is not clear whether TDP-43 inclusions 
are SG subtypes or whether they are functionally distinct 
[32, 36, 37]. Optogenetic induction of SGs can potentiate 
TDP-43 accumulation [38], but TDP-43 can also function 
as a regulator of stress granule dynamics [39], indicative of 
a bidirectional relationship.
ER stress and subsequent downstream signalling have 
been strongly linked to MND [40–42]. The ER stress-
induced protein CHOP is upregulated [40, 42] as are other 
markers associated with ER stress: BiP [43], phospho-eIF2α 
[44], and protein disulfide isomerase (PDI) [45]. In a screen 
for putative protein biomarkers of MND, the chaperones 
ERp57, calreticulin, and PDI featured prominently [46], with 
genetic variants in the latter being reported as risk factors 
for MND [47]. Morphologically, ER abnormalities in the 
disease state have also been observed by electron micros-
copy [43, 48]. A subset of vulnerable motor neurons was 
also found to be particularly susceptible to ER stress and the 
subsequent stress-induced death was ameliorated by salubri-
nal, a drug targeting ER stress [49]. In vitro, tunicamycin is 
widely used to induce endoplasmic reticulum (ER) stress as 
it blocks N-glycosylation of proteins [50], which ultimately 
leads to accumulation of proteins in the ER.
In this study, we show that the ER-stressor tunicamycin 
induces the accumulation of endogenous TDP-43 into cyto-
plasmic inclusions. When tunicamycin treatment is admin-
istered to NSC-34 cells alongside a CK1 inhibitor, TDP-43 
cytoplasmic accumulation is markedly reduced, in addition 
to its phosphorylation and segregation into the RIPA-insol-
uble/urea-soluble fraction, which suggests that CK1 plays a 
role in the mislocalisation of TDP-43 observed under condi-
tions of ER stress.
Materials and Methods
All chemicals were purchased from Fisher Scientific (Lough-
borough, Leicestershire, UK) unless otherwise stated. Phar-
macological inhibitors were sourced as indicated: tunicamy-
cin (Cat T7765), PF670462 (Cat SML0795) (Sigma-Aldrich, 
Gillingham, Dorset, UK), sodium arsenite (Cat #12897692), 
sorbitol (Cat #10396733) (Fisher Scientific), and D 4476 
(Cat CAY13305) (Cambridge Bioscience, Cambridge, UK). 
Dimethyl sulphoxide was used as a vehicle in cell culture 
treatments.
Primary antibodies used were for the TDP-43 N-terminus 
(Proteintech Group, Manchester, UK; RRID:AB_615042, 
1:500 (ICC) or 1:1000 (IB)), Phospho(409/410)-TDP-43 
(Proteintech Group; RRID:AB_66318, 1:500), BiP/Grp78, 
(Proteintech; RRID: AB_2119855, 1:500), TIAR (BD Bio-
sciences; RRID:AB_397742, 1:500), G3BP1 (Proteintech 
Group; RRID: AB_2232034, 1:500) and β-actin (Sigma-
Aldrich; RRID:AB_476692, 1:1000).
Cell Culture
Motor neuron-like NSC-34 cells (RRID:CVCL_D356, a 
kind gift from Dr. Adrian Higginbottom, Sheffield Institute 
of Translational Neuroscience, Sheffield, UK) [51] were cul-
tured in Dulbecco’s Modified Eagle’s Medium (DMEM Cat 
BE12-914F, Lonza, Slough, Berkshire, UK), supplemented 
with 10% foetal bovine serum (FBS) (Cat FCS-SA/500, 
Labtech, Uckfield, East Sussex, UK), 2 mM l-glutamine 
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(Cat #35050061), 100 U/mL penicillin, and 100 µg/mL 
streptomycin (combined Cat #15140122) (all Thermo 
Fisher Scientific, Paisley, Renfrewshire, UK) to a maxi-
mum of passage 30. Cells were incubated at 37 °C and 5% 
 CO2 in a humidified atmosphere. For differentiation, cells 
were seeded and cultured in full growth medium (above) 
for 24 h, then differentiated for 7 days in DMEM-F12 (Cat 
BE04-687F, Lonza) supplemented with 1% FBS, 100 U/
mL penicillin, 100 µg/mL streptomycin, 1% non-essential 
amino acids and 1 µM retinoic acid (Cat R2625) (Sigma-
Aldrich) [52, 53]. For immunofluorescence experiments, 
cells were cultured on gelatin-coated glass coverslips (Cat 
G1393, BioReagent, Sigma-Aldrich). Cells were tested for 
mycoplasma contamination by PCR. NSC-34 cells are not 
listed on the ICLAC Register of Misidentified Cell Lines.
Cell Lysis
Separation of the RIPA-soluble and urea-soluble fractions 
was performed as previously described [54]. In brief, treated 
cells were washed twice in ice-cold phosphate-buffered 
saline (PBS) and harvested in PBS. Cells were pelleted at 
3000×g for 5 min (4 °C) and re-suspended in 6 × volume 
of lysis buffer (RIPA buffer: 50 mM Tris–HCl (pH 8.0), 
150 mM sodium chloride, 1% Igepal CA-630 (NP-40 substi-
tute, Sigma-Aldrich), 0.5% sodium deoxycholate, 0.1% SDS, 
1 mM sodium fluoride, 1 mM sodium orthovanadate, and 
Complete Protease Inhibitor cocktail (Cat #11836170001, 
Roche Diagnostics, Burgess Hill, West Sussex, UK)). Lysis 
was performed for 30 min on ice, followed by centrifugation 
at 100,000×g for 30 min (4 °C) to yield the RIPA-soluble 
fraction as the supernatant. The resultant insoluble pellet 
was washed in RIPA buffer, re-centrifuged and resuspended 
in urea-containing buffer (30 mM Tris–HCl (pH 8.5), 7 M 
urea, 2 M thiourea, 4% CHAPS, 1 mM sodium fluoride, 1 
mM sodium orthovanadate, and Complete Protease Inhibi-
tor cocktail) and sonicated, followed by centrifugation at 
100,000×g for 30 min. The supernatant was taken as the 
(RIPA) insoluble fraction.
Determination of Protein Concentration
Protein concentration in the RIPA-soluble fraction was 
determined using the bicinchoninic acid (BCA) method [55], 
using a Pierce BCA Protein Assay Kit (Cat #23225, Thermo 
Fisher Scientific). In brief, protein samples were incubated 
for 30 min at 37 °C with BCA solution (BCA with 2% (v/v) 
copper (II) sulphate). Post-incubation, absorbance at 562-nm 
was measured using a plate reader (ELx800, BioTek, Swin-
don, UK, UK). Sample concentration was determined using 
bovine serum albumin (BSA) as a standard at concentrations 
from 0 to 1 mg/mL. As the BCA assay is incompatible with 
7 M urea, the Pierce 660 nm Protein Assay Kit (Cat #22662, 
Thermo Fisher Scientific;) was used according to the manu-
facturer’s instructions. In brief, samples were incubated with 
reagent for 10 min at room temperature before reading the 
absorbance at 660-nm. The protein concentration was pro-
portional to the absorbance and was calculated relative to a 
BSA standard curve (0–2 mg/mL).
SDS‑PAGE and Immunoblotting
Protein samples were separated by electrophoresis (120 V 
for 90 min) on a polyacrylamide gel containing 12% acryla-
mide in the absence of reducing agent. After SDS-PAGE, 
proteins were transferred to polyvinylidene fluoride (PVDF) 
membranes for 75 min at 125 V (Bio-Rad). The PVDF mem-
branes were incubated for 2 h in blocking solution (5% (w/v) 
milk powder, 2% (w/v) BSA in TBS + 0.1% (v/v) Tween-
20 (TBST)) and then incubated overnight in primary anti-
body (5% (w/v) milk powder (or BSA for phosphorylated 
epitopes), in TBS). The PVDF membranes were washed 
4 × 10 min with TBST before the addition of secondary 
antibody (HRP-conjugated anti-IgG (Cat #65-6120 and # 
A16072; 5% (w/v) milk powder in TBST, 1:5000 (Thermo 
Fisher Scientific)) for 1 h, followed by 4 × 10 min washes 
with TBST. Protein bands were visualized by chemilumi-
nescence (Clarity Western ECL Blotting Substrate, Cat 
#1705061, Bio-Rad) using a G:BOX and GeneTools soft-
ware (Syngene, Cambridge, UK).
Lambda (λ) Phosphatase Treatment
NSC-34 cells were lysed in minimal lysis buffer (50 mM Tris 
(pH7.4), 1% Triton X-100 and 0.5% sodium deoxycholate, 
followed by incubation with λ phosphatase (Cat #P0753L, 
New England Biolabs, Hitchin, UK) according to the manu-
facturer’s instructions followed by SDS-PAGE as described.
Immunofluorescence Microscopy
Cells were cultured on gelatin coated glass coverslips 
(BioReagent, Sigma Aldrich). After treatment, cells were 
fixed in 4% paraformaldehyde for 10 min then washed in 
PBS. Cells were subsequently permeabilised in 0.5% Triton 
X-100, washed in PBS and incubated with blocking buffer 
(0.5% fish skin gelatin (Cat G7041, FSG, Sigma) in PBS) for 
1 h. Coverslips were incubated with primary antibody for 1 h 
(in 0.5% FSG, 0.5% Triton X-100 in PBS), washed in PBS 
and incubated for 1 h in secondary antibody (0.5% FSG, 
0.5% Triton X-100 in PBS and either Alexa Fluor 488 or 594 
(Cat A-21202 or R37119, Thermo Fisher Scientific). After 
washing, coverslips were incubated with 1 µg/mL DAPI (Cat 
#62248, Thermo Fisher) for 5 min and mounted on micro-
scope slides with Prolong Diamond mounting medium (Cat 
P36961, Thermo Fisher Scientific). Images were collected 
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on a Zeiss Axioimager.M2 upright microscope using 
20 × plan apochromat or 63x plan apochromat objectives 
as indicated and captured using a Coolsnap HQ2 camera 
(Photometrics, Tucson, AZ, USA) through Micromanager 
software v1.4.23. Specific band pass filter sets for DAPI, 
FITC and Texas Red were used to prevent bleed through 
from one channel to the next. Images were then processed 
and analysed using ImageJ (NIH, USA).
Cell Viability Assays
For cell viability assays, NSC-34 cells were cultured in 
96-well plates. An aliquot of culture medium was extracted 
and added to an equivalent volume of lactate dehydroge-
nase reaction buffer (Pierce LDH Cytotoxicity Assay, Cat # 
88953, Thermo Fisher), incubated for 30 min and absorb-
ance read at 490 nm using a plate reader. The cells and 
remaining medium were incubated with CellTiter 96 AQue-
ous One or Cell Titer Glo (Cat G3580 or G9241, Promega, 
Southampton, UK) and, respectively, absorbance at 490 nm 
or luminescence recorded.
Statistical Analysis
All experiments are n = 3 unless otherwise indicated, where 
n indicates a biological replicate. Statistical tests were 
either Student’s t test (control versus tunicamycin) or one-
way ANOVA (multiple groups) with Tukey’s post hoc test; 
p < 0.05 (*), p < 0.01 (**) p < 0.001 (***) or p < 0.0001 
(****). All statistical analyses were performed using Graph-
Pad Prism 7 (GraphPad Software, Inc., La Jolla, CA, USA). 
D’Agostino Pearson normality testing was performed which 
showed data (Fig. 2) to be non-normal. However, ANOVA 
has been shown to be robust even with non-Gaussian distri-
butions [56]. Tests for outliers and sample calculation were 
not performed.
Ethical Approval
Institutional ethical approval was not required for this study.
Results
Cellular Stress Induces Formation of TDP‑43 
Inclusions and Stress Granules
Compounds were tested in NSC-34 cells to assess their 
ability to drive the formation of TDP-43-positive inclu-
sions and stress granules (Fig. 1). The ER stressor, tuni-
camycin (0.1 µM, 24 h), was able to generate perinuclear 
TDP-43 inclusions without nuclear depletion, though these 
were TIAR- and G3BP1- negative (Fig. 1a and b). The 
tunicamycin-induced TDP-43 inclusions are large in size, 
often with a single large inclusion per cell (Fig. 1), and 
resemble the rounded TDP-43 inclusions found in the motor 
cortex of people with MND [57].
Treatment with sodium arsenite (500 µM, 1 h) resulted in 
generation of TIAR- and also G3BP1-positive SGs. There 
were multiple granules per cell, producing an exclusively 
cytosolic speckled pattern, with a broadly even distribution 
throughout the cytosol. However, treatment with sodium 
arsenite failed to generate TDP-43-positive inclusions 
Fig. 1  Induction of ER, oxidative and osmotic stress in NSC-34 
cells. NSC-34 cells were cultured as described and differentiated 
for seven days and treated with either vehicle, 0.1  µM tunicamycin 
(24 h) sodium arsenite (500 µM, 1 h) or 400 mM sorbitol (1 h). Cells 
were subsequently fixed and immunocytochemistry was performed as 
described, using primary antibodies against TDP-43, and a TIAR or 
b G3BP1 as indicated using a 63 × objective. Scale bars, 10 µm. n = 3 
(biological replicates)
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(Fig. 1). The hyperosmolar stressor, sorbitol (400 mM, 1 h) 
similarly generated TIAR- and also G3BP1-positive gran-
ules, and resulted in TDP-43-positive inclusions (Fig. 1). 
These inclusions were punctate and cytosolic, visualised as 
multiple small speckles, and showed a similar morphology 
to the circumferential TDP-43 inclusions reported by Tan 
et al. [57], although the inclusions in that study were more 
skein-like than the multiple punctate structures seen in our 
work. In addition, Tan et al. used human post-mortem tissue 
as opposed to the cultured cells use here [57]. Immunocy-
tochemistry showed that only a proportion of the sorbitol-
induced SGs also stained positive for TDP-43, indicating 
at least two subpopulations of inclusions (Fig. 1). Taken 
together, these data show that cellular stress can result in 
the accumulation of TDP-43 in cytosolic inclusions, the 
morphology of which is dependent on the inciting stressor.
Tunicamycin‑Induced ER Stress Does Not Affect 
TDP‑43 Levels or Cell Viability
Tunicamycin induced the most robust formation of TDP-
43-positive inclusions and was thus selected for further char-
acterisation. Under conditions of ER stress, chaperones such 
as Grp78 are known to become activated, a response which 
is proposed to support correct folding of accumulating pro-
teins [58]. The abundance of the ER chaperone Grp78 (aka 
BiP) was determined by immunoblotting (Fig. S1). Tuni-
camycin treatment resulted in a 3.5-fold increase in Grp78 
immunoreactivity (Fig. S1a and b), demonstrating that ER 
stress is occurring in these cells. There were no concomitant 
increases in abundance of soluble TDP-43 (Fig. S2a and 
b) and this concentration of tunicamycin had no effect on 
cell viability, as determined by the CellTiter Glo assay (Fig. 
S1c). These data show that the selected concentration of 
tunicamycin induces a robust ER stress response, but does 
not affect overall cell viability.
CK1 Inhibition Reduces the Formation of TDP‑43 
Positive Inclusions
CK1ε has been identified as the only TDP- 43 kinase able to 
significantly potentiate the toxic effects of TDP-43 Q331 K 
over-expression in Drosophila [22]. However, CK1δ has 
also been linked to MND [26]. Therefore, in this study, a 
two pharmacological inhibitors of CK1 were used, D4476 
and PF670462 (both 10 µM, 24 h) [59, 60]. In untreated 
cells, TDP-43 positive inclusions were extremely sparse 
(in 1.3% of cells), whereas tunicamycin treatment induced 
formation of TDP-43 positive inclusions in 27% of cells. 
Co-incubation of tunicamycin with the CK1 inhibitors sig-
nificantly reduced the effect of tunicamycin by 64% (D4476) 
or 82% (PF670462) as determined by percentage cells with 
TDP-43 positive inclusions (Fig. 2). Incubation of cells with 
either inhibitor alone had no effect on TDP-43 localisation or 
inclusion formation (data not shown). These data show that 
tunicmycin-induced ER stress potentiates TDP-43 accumu-
lation through a CK1-dependent mechanism.
In order to test the effects of the CK1 inhibitors on cell 
viability, a two complementary assays were performed. The 
LDH cytotoxicity assay was used, which is a measure of 
extracellular LDH and hence membrane integrity. Tunica-
mycin treatment had no effect on LDH release, at concentra-
tions up to 10 µM (Fig. 3a). Similarly, co-incubation with the 
CK1 inhibitors had no effect on LDH release (Fig. 3a). The 
CellTiter 96 AQueous One Solution Cell Proliferation Assay 
Fig. 2  Ability of CK1 inhibitors to block TDP-43 aggregation. NSC-
34 cells were treated with 0.1 µM tunicamycin (Tn) ± 10 µM D4476 
or 10 µM PF670462, as indicated. Cells were subsequently fixed and 
a immunocytochemistry was performed as described, using primary 
antibodies against TDP-43 using a 20 × objective. Scale bars, 50 µm 
and b the percentage of cells with cytoplasmic inclusions was calcu-
lated. Each data point refers to one field of view, where n = 4 (bio-
logical replicates). Statistical significance was assessed using one way 
ANOVA with Tukey’s post hoc test. Horizontal lines (blue) indicate 
mean and SD
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was used to measure the cells’ ability to reduce the MTS 
tetrazolium dye to a coloured formazan product. No change 
in absorbance was seen with treatment of cells with 0.1 µM 
tunicamycin. However, treatment of cells with tunicamycin 
at concentrations ranging from 0.5 µM to 10 µM resulted 
in a significant decrease in absorbance, indicating impaired 
cellular metabolic capabilities (Fig. 3b). Co-incubation of 
tunicamycin with either of the CK1 inhibitors failed to res-
cue the deficiencies in cellular metabolism (Fig. 3b). Thus 
treatment of NSC-34 cells with concentrations of tunicamy-
cin up to 10 µM does not cause frank cell death. However, 
at concentrations above 0.5 µM, there is evidence of more 
subtle metabolic disturbances, which are not reversed by 
CK1 inhibition.
CK1 Inhibition Reduces Tunicamycin‑Induced 
TDP‑43 Phosphorylation and Accumulation 
in the RIPA‑Insoluble Fraction
Immunocytochemistry indicated that signalling downstream 
of ER stress induction by tunicamycin resulted in cytoplas-
mic accumulation of TDP-43. To further characterise this pro-
cess, cell fractionation (RIPA soluble and RIPA insoluble/urea 
soluble fractions) and immunoblotting were used as previously 
reported [54].
Immunoblot analysis of the RIPA-soluble fraction showed 
no significant changes in either TDP-43 or phospho-TDP-43 
(S409/S410) (pTDP-43) immunoreactivity with tunicamycin 
treatment ± CK1 inhibitors (Fig. 4a and b). All total TDP-43 
was at a molecular weight consistent with a monomer and this 
was recapitulated with pTDP-43 immunoblotting, although 
the latter is demonstrably expressed at very low levels in the 
soluble fraction. Lysates from this fraction were treated with 
λ phosphatase and the consequent molecular weight shift in 
the pTDP-43 monomer confirms its identity, suggesting other 
bands to be non-specific (Fig. S2a).
In the RIPA-insoluble, urea-soluble fraction, probing for 
total TDP-43, the predominant immunoreactive band also cor-
responds to the molecular weight of the monomer. There is 
no significant change in immunoreactivity with tunicamycin 
treatment with or without CK1 inhibitors (Fig. 4c and d). In 
this fraction, immunoblotting for phospho-TDP-43 detected 
several immunoreactive bands, corresponding to the pre-
dicted TDP-43 monomer and TDP-43 dimer, and also higher 
molecular weight assemblies. The immunoreactive pTDP-43 
bands broadly correspond to the pattern of bands detected by 
total TDP-43 albeit with varying intensities of the different 
molecular weight species detected. In order to verify the iden-
tity of pTDP-43 immunoreactive bands in the RIPA-insoluble 
fraction, the reducing agent DTT was used (1 mM in sample 
buffer) on the basis that higher molecular weight TDP-43 spe-
cies have been suggested to be dependent on thiol linkages 
[54]. Both the high molecular weight species of pTDP-43 
(approximately 250 kDa) and the putative pTDP-43 dimer 
showed substantial reductions in immunoreactivity in the 
presence of DTT. No other bands were seen to be sensitive to 
DTT (Fig. S2b).
Tunicamycin treatment induced significant increases in 
higher molecular weight pTDP-43 species (Fig. 4c and d). 
This effect of tunicamycin was reduced by co-incubation with 
either of the CK1 inhibitors D4476 or PF670462 (Fig. 4c and 
d). Incubation of cells with either inhibitor alone had no effect 
on TDP-43 immunoreactivity in the RIPA-soluble or insoluble 
fractions (data not shown).
Overall, ER stress signalling induced by tunicamycin has 
no effect on TDP-43 abundance in the RIPA-soluble fraction. 
However, significant increases in high molecular weight, phos-
phorylated TDP-43 species are seen in the RIPA-insoluble/
urea-soluble fraction after tunicamycin treatment. The abun-
dance of these species is substantially reduced by co-treatment 
of tunicamycin with a CK1 inhibitor.
Fig. 3  Impact of ER stress on cell viability. Cell viability was 
assessed using a the LDH Cytotoxicity Assay and b the CellTiter 
96 AQueous One Solution Cell Proliferation Assay. Horizontal lines 
indicate statistical significance for all groups. Each point represents 
the mean (n = 3 biological replicates) with error bars as SD. Statisti-
cal significance was assessed using one way ANOVA with Tukey’s 
post hoc test. Significance denotes statistical difference from vehicle 
(i.e. 0 µM tunicamycin)
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Fig. 4  Fractionation and immunoblot analysis of TDP-43. NSC-
34 cells were treated with vehicle control or 0.1  µM tunicamycin 
(Tn) ± 10 µM D4476 or PF670462. a RIPA-soluble and c RIPA-insol-
uble/urea-soluble fractions were prepared, followed by SDS-PAGE 
and immunoblot, probing for TDP-43 and pTDP-43. Densitometric 
analysis was performed on blots from the soluble fraction (b) and 
the insoluble fraction (d). Phospho-TDP-43 densitometry represents 
the 80 kDa immunoreactive band. * = high molecular weight pTDP-
43 and # = monomeric pTDP-43. Each point represents a biological 
replicate (n = 3) with error bars as SD. Statistical significance was 
assessed using one way ANOVA with Tukey’s post hoc test. Horizon-
tal lines (black) indicate mean and SD
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Discussion
Here we show that stress treatments of cultured NSC-34 
cells induced different patterns of TDP-43 and TIAR/
G3BP1-positive inclusions, supporting the hypothesis that 
in sporadic MND, TDP-43 aggregation is potentiated by 
cellular stress. Here we have focussed on chemical induc-
tion of ER stress, showing that tunicamycin-induced ER 
stress signalling can cause profound accumulation of TDP-
43 in NSC-34 cells. In both this study and the work by 
Leggett et al. [61], tunicamycin induces the formation of a 
small number of large cytoplasmic inclusions, rather than 
the numerous puncta seen with some other stressors [23]. 
ER stress has been strongly implicated in the pathogenesis 
of MND, and our study is among the first to show that 
ER stress can induce cytoplasmic accumulation of endog-
enous TDP-43, a major pathological hallmark of MND, 
although this has been shown using thapsigargin, which 
also induces ER stress [62, 63] This process is partially 
blocked by pharmacological inhibition of CK1, suggesting 
a key role for CK1.
Despite its prominence in MND, ER stress has received 
modest attention. Our data show that CK1 plays a vital role 
in TDP-43 cytoplasmic inclusion formation under condi-
tions of chronic ER stress. A role for CK1 is supported 
in previously published reports [22, 26, 27], which has 
relevance for the pharmacological targeting of TDP-43 
aggregation [14, 27, 28, 30].
The data presented here also offer insight into the rela-
tionship between SGs and TDP-43 inclusions. SGs are 
considered to be protective against acute stress [32]. In 
our study we find no evidence of co-localisation between 
the SG markers TIAR and G3BP1 and endogenous TDP-
43 following ER stress. This is in line with recent findings 
showing a lack of association between SG markers and 
mature TDP-43 inclusions [35]. We also show that stress-
ors can induce formation of TDP-43 inclusions with sub-
stantially different morphology, here with osmotic stress 
giving rise to a different pattern than that induced by ER 
stress. Our findings support existing evidence that differ-
ent cellular stressors give rise to differing responses in 
terms of formation of SGs and TDP-43 inclusions, with a 
considerable diversity in SGs [64]. This is in agreement 
with previous work demonstrating the heterogeneity in 
response to cell stress with regard to TDP-43 inclusion 
and SG formation [63, 65] TDP-43 has been reported 
to associate with SGs under certain conditions [31, 66]. 
For example, Colombrita et al. [66] generated sodium 
arsenite-induced TDP-43/TIAR immunopositive inclu-
sions in a TDP43 over-expressing system. Other studies 
have previously reported findings on TDP-43 in non-
TIAR positive structures in agreement with our findings 
[35, 55, 67], including generation of the same pattern of 
sorbitol-induced punctate TDP-43 accumulation in non-
TIAR positive SGs [67]. It is of interest that hyperosmo-
lar stress has also been shown to cause mislocalisation of 
FUS [68]. The relevance of this to sporadic MND is the 
implication that the development of TDP-43 aggregates in 
patients and the precise location and co-localisation with 
other markers could reflect differences in underlying cel-
lular stresses. It is possible that, in patients with sporadic 
disease, different cellular stresses, for example ER stress 
and oxidative stress, lead to TDP-43 aggregation through 
distinct pathways and this may account for the recent find-
ing of different TDP-43 inclusion morphologies in MND 
and frontotemporal dementia, namely the rounded and 
circumferential morphologies [58]. Furthermore, the dif-
ferences in underlying stress may account the multiplicity 
of signalling pathways and TDP-43 kinases implicated in 
neurodegeneration, ranging from CK1 to cyclin-dependent 
kinase and glycogen synthase kinase 3 [22, 23, 25, 69, 70].
Biochemical methods were used to understand the rela-
tionship between accumulation of TDP-43, phosphorylation 
and potential aggregation. Immunoblotting data showed 
that tunicamycin treatment did not have any significant 
impact on levels of total TDP-43 or phospho-TDP-43 in the 
RIPA-soluble fraction (Fig. 4) and the very low pTDP-43 
immunoreactivity agrees with the findings of others [71]. 
However, it would be expected that any aggregated spe-
cies would be present in the RIPA-insoluble, urea-soluble 
fraction. Indeed this proved to be the case, with substan-
tial increases in multiple phosphorylated TDP-43 species. 
The specificity of the higher molecular weight species was 
demonstrated by the inclusion of the reducing agent DTT 
in the sample buffer in a subset of samples. This caused a 
decrease in immunoreactivity of the higher molecular weight 
phospho-TDP-43 species, confirming the findings of Cohen 
et al. [54], who found higher order TDP-43 species to be 
dependent on disulphide bonds. The tunicamycin-induced 
increase in phospho-TDP-43 was lowered by the CK1 inhibi-
tors, D4476 and PF670462. The ability of kinase inhibi-
tion to block ER-induced phosphorylation of TDP-43 and 
concurrently, TDP-43 cytoplasmic accumulation, suggests 
that stress-induced TDP-43 phosphorylation is an early step 
in sporadic MND, followed by accumulation of TDP-43 in 
cytoplasmic inclusions in the RIPA-insoluble fraction. This 
is in line with previous findings, which showed the ability of 
D4476 to reduce the ethacrynic acid-induced phosphoryla-
tion of TDP-43 [72].
Furthermore, in this study, TDP-43 phosphorylation 
and accumulation were not accompanied by any increase 
in cellular LDH release or reduction in the cells’ ability 
to metabolise the MTS tetrazolium dye (at 0.1 µM tuni-
camycin). This finding suggests that our system may be 
modelling the early stages of sporadic disease, showing 
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that inclusions of TDP-43 are not initially concurrent with 
cell death or metabolic disturbance. This is consistent with 
the notion of TDP-43 accumulating as part of a protective 
response to stress, analogous to the role of stress granules. 
However, if the concentration of tunicamycin is raised to 
0.5 µM or above, then the cells exhibit substantial deficits 
in their ability to metabolise the MTS tetrazolium dye. 
Notably, cells still do not exhibit signs of frank cell death 
(i.e. membrane permeabilisation), even at the highest con-
centrations of tunicamycin. Co-incubation of cells with 
a CK1 inhibitor shows this to have a beneficial effect at 
the earliest stages, i.e. blocking TDP-43 phosphorylation 
and cytosolic accumulation. However, once metabolic dis-
turbances occur at higher concentrations of tunicamycin, 
kinase inhibition has no effect. This paradigm has been 
recapitulated in a genetic model of MND, over-expressing 
mutant TDP-43, where TDP-43 aggregation preceded any 
cell death [73].
Recent work has shown a correlation between phospho-
TDP-43 and CK1 levels in sporadic MND patients and that 
CK1ε could act as a TDP-43 kinase in human motor neu-
rons [21]. Motor neurones derived from C9ORF72 hexa-
nucleotide expansion carriers display a similar phenotype 
to the NSC-34 cells in this study, in terms of increased 
expression of Grp78 [74]. Also, circulating lymphocytes 
from individuals with sporadic MND show no change in 
total TDP-43, but CK1-dependent increases in phospho-
TDP-43, as seen in our study. [75]. Taken together these 
findings suggest that our model replicates some of the 
pathological correlates of sporadic MND in humans.
The data shown here give insight into the chronology 
of events in a sporadic MND model. On encountering ER 
stress, cells up regulate chaperone expression e.g. Grp78. 
Signalling downstream of cellular stress also results in 
activation of kinases, such as CK1, which lead to phos-
phorylation of TDP-43 and accumulation in the insoluble 
fraction. At this point, the cells do not display any meta-
bolic deficiencies and the changes in TDP-43 modification 
and localization can be mitigated by small molecule CK1 
inhibitors. However, at higher levels of stress, reduced 
ability to metabolise MTS tetrazolium is observed and at 
this stage, CK1 inhibitors have no effect. This underscores 
the importance of early diagnosis of MND as it suggests 
that the earliest pathological changes may be reversed 
by small molecules, but that this approach may be less 
effective once there is metabolic disturbance in the motor 
neurons.
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